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Metabolic reprogramming is critical to oncogenesis,
but the emergence and function of this profound
reorganization remain poorly understood. Here we
find that cooperating oncogenic mutations drive
large-scale metabolic reprogramming, which is
both intrinsic to cancer cells and obligatory for the
transition to malignancy. This involves synergistic
regulation of several genes encoding metabolic en-
zymes, including the lactate dehydrogenases LDHA
and LDHB and mitochondrial glutamic pyruvate
transaminase 2 (GPT2). Notably, GPT2 engages acti-
vated glycolysis to drive the utilization of glutamine
as a carbon source for TCA cycle anaplerosis in co-
lon cancer cells. Our data indicate that the Warburg
effect supports oncogenesis via GPT2-mediated
coupling of pyruvate production to glutamine catab-
olism. Although critical to the cancer phenotype,
GPT2 activity is dispensable in cells that are not fully
transformed, thus pinpointing a metabolic vulnera-
bility specifically associated with cancer cell pro-
gression to malignancy.
INTRODUCTION
Many types of cancer cells exhibit pronounced metabolic
reprogramming compared with non-transformed cells. The
most well documented of these metabolic alterations is the
activation of aerobic glycolysis; i.e., the Warburg effect (War-
burg, 1956). In addition to glycolytic activation, cancer cells
frequently activate fatty acid biosynthesis and glutamine con-
sumption (DeBerardinis et al., 2007; Kuhajda, 2000; Wise et al.,
2008). More recently, this metabolic induction has been shown
to be an essential feature of the transformed state. A number
of metabolic enzymes activated in cancerous cells have been
found to be critical for tumorigenesis. These include enzymes
involved in glycolysis (Christofk et al., 2008; Fantin et al., 2006;
Telang et al., 2006), fatty acid biosynthesis (Bauer et al., 2005;
Hatzivassiliou et al., 2005), and glutaminolysis (Gao et al.,Ce
This is an open access article under the CC BY-N2009; Son et al., 2013; Wise et al., 2008; Yuneva et al., 2007).
It is also clear that specific oncogenic mutations, for example,
those activating the Ras-Akt-mTOR pathways, are critical for
activation of common cancer-associated metabolic activities
(Deprez et al., 1997; Elstrom et al., 2004; Gaglio et al., 2011;
Guo et al., 2011; Kole et al., 1991; Ramanathan et al., 2005;
Telang et al., 2007; Vizan et al., 2005; Ying et al., 2012). Little
is known, however, about the emergence of metabolic reprog-
ramming and its coordination during the cellular transition to
malignancy, due, at least in part, to the presence of multiple
causative genetic alterations in cancerous tissues.
Mechanistic insights into the complex structure of cellular
regulation underlying malignant cell transformation come from
exploration into how distinct oncogenic mutations cooperate
to induce such a profound transition (Kinsey et al., 2014; Lloyd
et al., 1997; McMurray et al., 2008; Sewing et al., 1997; Smith
and Land, 2012; Xia and Land, 2007). In this context, it is notable
that numerous genes essential to tumorigenesis can readily be
identified by virtue of their synergistic response to cooperating
oncogenic mutations. As indicated by genetic perturbation ex-
periments, such genes, termed cooperation response genes
(CRGs), contribute to the malignant phenotype at a frequency
of >50% (McMurray et al., 2008). CRGs affect diverse cellular
mechanisms, including signaling, gene expression, motility,
and certain aspects of metabolism, thus pinpointing tangible
links by which oncogenic mutations affect metabolic reprogram-
ming, among other effects.
Here we report the emergence ofmetabolic reprogramming as
a function of oncogene cooperation. We utilized a model of
oncogenesis in which a constitutively active Ras12V allele and a
dominant-negative p53175H allele cooperate to rapidly convert
colon crypt cells to malignant cancer cells in vitro (McMurray
et al., 2008; Xia and Land, 2007). This enabled direct elucidation
of how the expression of individual oncogenic alleles affects
metabolic functionality as opposed to dissecting out the
multifaceted consequences of inhibiting oncogenic pathways
in tumor-derived tissues. We find that cooperation of both
p53175H and Ras12V is required and sufficient to induce the ma-
jority of cancer cell metabolic phenotypes, including shunting
of glucose-derived carbon to lactate, increased glutamine con-
sumption, and fatty acid biosynthesis induction. Furthermore,
our results indicate that oncogenic p53 and Ras cooperativelyll Reports 17, 821–836, October 11, 2016 ª 2016 The Authors. 821
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regulate the expression of several metabolic genes we find to be
essential for tumorigenesis. These genes include both isoforms
of lactate dehydrogenase (LDHA and LDHB), which are induced
and repressed, respectively, and GPT2, a mitochondrial gluta-
mate-dependent transaminase that is also oncogenically
induced. Reversion of any of these oncogenically driven changes
substantially attenuates tumorigenesis. Notably, we show that
induction of GPT2 exploits the generation of alanine from the
glycolytic end product pyruvate as a means to drive alpha-keto-
glutarate formation from glutamate, thus facilitating entry of
glutamine carbon into the tricarboxylic acid (TCA) cycle. We
also show that this activity is critical to the cancer cell phenotype
while being dispensable in cells that are not fully transformed,
thus pinpointing a metabolic vulnerability specifically associated
with cancer cell proliferation and carcinogenesis. Together, our
data provide evidence of a critical link between activated
glycolysis and glutamine-dependent TCA cycle anaplerosis,
suggesting that production of pyruvate to enable glutamine
catabolism is a critical contribution the Warburg effect provides
toward oncogenesis.
RESULTS
Oncogenic Ras and Mutant p53 Cooperatively Induce
the Cancer Cell Metabolic Program
Themostwidely describedmetabolic attribute of cancerous cells
is the activation of glycolysis with increased secretion of the
glycolytic endproduct lactate; i.e., theWarburg effect (Figure 1A).
It remains unclear, however, at what point of the multi-step pro-
cess of carcinogenesis the glycolytic phenotype emerges and
whether this transition is driven by cell-intrinsic mechanisms or
by selective forces in the cancer microenvironment (e.g., oxygen
limitation). We have extensively used young adult murine colon
(YAMC) cells (Whitehead et al., 1993) transduced with activated
Rasandmutant p53 to investigate themolecularmechanismsun-
derlying the cooperative nature of malignant cell transformation,
which has revealed cancer cell-specific vulnerabilities relevant to
human disease (Kinsey et al., 2014; McMurray et al., 2008; Smith
and Land, 2012; Xia and Land, 2007; Experimental Procedures).
This model is therefore well suited to investigate the metabolic
changes associated with the transition to malignancy. It consists
of non-transformed parental YAMC cells as well as transduction
with either control vectors (bleomycin/neomycin control [BN])
or vectors expressing oncogenic HRas12V (Ras cells), mutant
p53175H (mp53 cells), or both oncogenic alleles together (mp53/
Rascells). For all transducedcells, low-passagepolyclonal deriv-Figure 1. Oncogenic Mutations Act Synergistically to Induce the Canc
(A) Schematic of central carbon metabolism.
(B–D) Extracellular lactate secretion (B), glucose consumption (C), and glutami
(mp53/Ras), mp53 alone, Ras alone, or empty vector (BN) cells.
(E) Measurement of fatty acid biosynthesis.
(B–E) Data are means + SE.
(F) Partial least-squares discriminant analysis of metabolic concentrations and th
(G–J) Absolute intracellular metabolite concentrations determined by LC-MS/MS
(K) Oncogenic cooperativity and allele dominance in metabolic reprogramming o
Statistically significant differences were assessed by ANOVA as indicated in the
Tables S1–S4.atives were utilized to minimize the effects of clonal variation on
specific phenotypes. Examination of lactate secretion indicated
that transduction of either oncogenic allele individually (i.e., either
p53175H or Ras12V) had a negligible effect on lactate excretion
compared with parental or control transduced cells (Figure 1B;
Table S1). In contrast, cells transduced with both activated Ras
and mutant p53 secreted substantially more lactate than control
cells or cells transducedwitheithermutant allele alone (Figure1B;
Table S1). Similarly, expression of both oncogenic alleles
increased glucose consumption to a greater extent than expres-
sion of either allele in isolation (Figure 1C; Table S1). In addition to
glycolytic activation, cancerous cells frequently increase gluta-
mine consumption and fatty acid biosynthesis (Bauer et al.,
2005; DeBerardinis et al., 2008; Kuhajda et al., 1994; Rashid
et al., 1997;Wise et al., 2008; Figure 1A). Expressionof oncogenic
RasV12 increased glutamine consumption compared with con-
trols, whereas p53175H expression had little effect (Figure 1D;
Table S1). Similar to the observations with glycolysis, co-expres-
sion of both oncogenic alleles cooperatively induced glutamine
consumption (Figure 1D; Table S1) and also induced fatty acid
biosynthesis relative to parental cells or cells expressing either
allele in isolation (Figure 1E; Table S1). Combined, these results
indicate that individual p53175H or Ras12V mutations in isolation
are not sufficient to drive common cancer cell metabolic pheno-
types but, rather, that these mutations cooperate to drive core
components of the tumor cell metabolic program, including
aerobic glycolytic activation, increased glutamine catabolism,
and activation of fatty acid biosynthesis. Further, the
finding that combined oncogene expression induces the
Warburg effect suggests that this central feature of the cancer
cell metabolic program can emerge independent of the environ-
mental conditions associated with tumors, such as oxygen
limitation.
The observed oncogene-induced metabolic changes do not
arise from simple differences in cell proliferation rates because
metabolic induction does not correlate with proliferation rates.
For example, mp53/Ras cells produce 2-fold more lactate than
Ras cells despite proliferating at similar rates (Figure 1B; Fig-
ure S1A). Further, Ras cells produce less lactate than mp53 cells
even though Ras cells proliferate faster (Figures 1A and 1D; Fig-
ure S1A). Moreover, although Ras overexpression can induce
senescence in specific contexts (Serrano et al., 1997), the robust
proliferation of Ras cells (Figure S1A) coupled with a lack of
senescence-associated b-galactosidase (b-gal) staining (Fig-
ures S1B and S1C) indicates that the Ras cells were not under-
going senescence at the time of metabolic measurements. Theirer Cell Metabolic Program
ne consumption (D) of the indicated derivatives of YAMC: combined mutant
e indicated YAMC derivatives.
. Data are means + SE.
f murine colon epithelial cells.
Experimental Procedures (Tables S1 and S4). See also Figures S1 and S2 and
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metabolic status thus cannot be attributed to a senescent cell
state. Taken together, these results demonstrate that the meta-
bolic alterations associated with these alleles are not simply a
function of either increased proliferation or senescence.
To examine how p53 and Ras mutations affect cell meta-
bolism more broadly, we employed liquid chromatography-
tandem mass spectrometry (LC-MS/MS) to globally profile
how metabolite concentrations are affected by p53175H and
Ras12V expression. The pool sizes of 69 different metabolites
are reported in Tables S2 and S3. Using the levels of these
metabolite pools, a partial least-squares discriminant analysis
(PLS-DA) model was constructed and subsequently validated
through cross-validation and permutation testing (Figures S1C
and S2D). In the resulting PLS-DA scores plot, the mp53/Ras
cells segregated from the non-transformed control cells (Fig-
ure 1F). The mp53 cells exhibited an intermediate separation
between the mp53/Ras cells and the controls, whereas the
metabolite concentrations of the Ras cells largely overlapped
with the control cells (Figure 1F). The metabolites whose levels
were significantly modulated by oncogene expression (Table
S4), and that contributed the most to the principal component
separation of the different cell types largely belonged to key on-
cogenically activated pathways such as glycolysis, nucleotide
biosynthesis, and lipid biosynthesis (Figure S1E). For glycolysis,
these oncogene-induced metabolites include fructose bisphos-
phate (FBP) (Figure 1G) and phosphoenolpyruvate (PEP) (Fig-
ure 1H), the production of which is heavily regulated and two
of the rate-controlling steps of glycolysis (Mazurek et al.,
2002; Voet and Voet, 2004). Various pentose phosphate
pathway metabolites were also induced, including ribose phos-
phate (Table S4) and 5-phosphoribosyl-a-pyrophosphate
(PRPP) (Figure 1I), whose production is a rate-controlling step
of de novo nucleotide biosynthesis (Voet and Voet, 2004).
Although these pentose phosphate pathway intermediates
were elevated in the transformed cells, the rate of oxidative
pentose phosphate flux, which generates ribose and nicotin-
amide adenine dinucleotide phosphate (NADPH) for biosyn-
thesis and protection from oxidative stress, was only modestly
increased in mp53/Ras cells (Figures S2A and S2B). Consistent
with the observed oncogenic increases in fatty acid biosyn-
thesis, joint expression of p53175H and RasV12 substantially
increased malonyl-coenzyme A (CoA) levels (Figure 1J), whose
production is the tightly regulated initial reaction of fatty acid
biosynthesis (Figure 1A; Brownsey et al., 2006).
Oncogenic p53 and Ras mutations cooperate to induce
many transformation-specific phenotypes (Kinsey et al., 2014;
McMurray et al., 2008; Smith and Land, 2012; Xia and Land,
2007), and, accordingly, many of the metabolic phenotypes
observed here were cooperatively induced (Figure 1K). How-
ever, a number of these metabolic activities were induced pre-
dominately by expression of either mp53 or oncogenic Ras. For
example, expression of oncogenic Ras predominantly drove
the increases in glutamine consumption (Figures 1D and 1K)
but did not affect lactate secretion (Figure 1B). Alternatively,
expression of mp53 was the major factor responsible for
increasing the various glycolytic and pentose phosphate me-
tabolites (Figure 1K). These mp53-induced concentrations
were the major factors that led to the intermediate segregation824 Cell Reports 17, 821–836, October 11, 2016of mp53 cells relative to the fully transformed and control cells
observed in the PLS-DA model (Figure 1F; Figures S1C–S1E).
Notably, the most widely defining feature of cancer metabolism
(i.e., induction of lactate secretion) was the most cooperatively
induced phenotype observed (Figures 1B and 1K). It has
been reported previously that oncogenic Ras expression in
non-transformed fibroblasts drives increased lactate secretion
(Gaglio et al., 2011). Our data indicate that these Ras-induced
changes are context-dependent and strongly suggest that,
although expression of different oncogenic alleles activates
specific metabolic activities, complete oncogenic reprogram-
ming involves cooperative action between both mp53 and
oncogenic Ras.
Cooperative De-regulation of Lactate Dehydrogenase
Activity Is Critical for Tumorigenesis
The highly cooperative induction of lactate production in trans-
formed cells suggests that a coordinated deregulation of LDH
isoform expression underlies emergence of the glycolytic pheno-
type during oncogenesis. LDHmediates conversion of the glyco-
lytic end product pyruvate to lactate, utilizing the cofactor NADH
(Figure 2A). The enzyme comprises a tetramer that can be
composed of any ratio of two isoforms, A and B, encoded by
distinct genes, LDHA and LDHB. Tetramers containing more
LDHA isoforms exhibit increased activity compared with those
with more LDHB (Read et al., 2001). Notably, LDHA expression
has been found to be both induced during and important for
tumorigenesis in some experimental models (Fantin et al.,
2006; Le et al., 2010). However, the coordination of LDHA and
LDHB isoform expression in controlling the glycolytic phenotype
of cancer cells is poorly understood. Analysis of LDH isoform
mRNA and protein levels in our model indicated that oncogenic
Ras is dominant in upregulating LDHA expression, whereas
mp53 is sufficient to suppress LDHB (Figures 2B and 2C). How-
ever, cooperation of both oncogenic alleles was required for the
LDHA:LDHB ratio observed in mp53/Ras transformed cells (Fig-
ures 2B and 2C), consistent with the pattern of lactate production
(Figure 1B). A similar switch in LDH isoform expression from
LDHB to LDHA was observed in human pancreatic (Figures
S3A and S3B) and prostate (Figures S3D and S3E) cancers
compared with respective normal tissues, indicating relevance
to human disease. In colon cancer, both LDH isoforms were
elevated (Figures S3G and S3H), suggesting that alternative
paths to LDH deregulation may exist. Further, although expres-
sion of LDHA and LDHB is significantly different in pancreatic
cancer specimens with both p53 and Ras mutations versus can-
cers with neither of thesemutations, LDH isoform expression did
not correlate with the p53/Ras mutational status of prostate or
colon tumor samples (Figures S3C, S3F, and S3H). Overall,
this suggests that LDH deregulation frequently emerges with
the cancer phenotype in general rather than being limited to
mutant p53- and Ras-driven cancers.
To test the effect of coordinated deregulation of both LDHA
and LDHB on oncogenic phenotypes, we reset their expression
inmp53/Ras cells to non-transformed levels using LDHB expres-
sion and LDHA short hairpin RNA (shRNA) constructs to increase
LDHB and decrease LDHA levels, respectively (Figures 2D and
2E). Analysis of lactate excretion upon targeting of LDH
A B C
D E F G
Figure 2. The LDH Isoform Switch Is Critical to Tumorigenesis
(A) Glycolysis schematic.
(B and C) LDHA or LDHB RNA expression (B) and protein expression (C) in parental (YAMC) cells or the indicated derivatives of YAMC cells: empty vector
(BN), mp53, Ras, and combined mutant cells (mp53/Ras).
(D and E) LDHA or LDHB RNA expression (D) and protein expression (E) in the indicated derivatives of PR cells: vector control (vector), LDHA knockdown plus
LDHB overexpression (LDH-rev), LDHA-kd, or LDHB overexpression (LDHB).
(B and E) RNA expression of LDHA or LDHB was measured via real-time PCR using gene-specific primers.
(D and C) Protein expression values of LDHA and LDHB were normalized to tubulin expression.
(F) Lactate secretion from the indicated derivatives of mp53/Ras cells.
(B–F) Data are means + SE. *p < 0.01 versus all other cell lines by Student’s t test.
(G) Tumor volumes 4 weeks after eight subcutaneous implantations of the indicated derivatives of mp53/Ras cells in the flanks of nude mice. Median tumor
volume is indicated by the horizontal line. *p < 0.01 versus all other cell lines by Student’s t test.
See also Figure S3.expression indicated that, individually, neither knockdown of
LDHA expression nor overexpression of LDHB were sufficient
to significantly reduce lactate secretion (Figure 2F). However,
when both LDHA expression was knocked down and LDHB
expression was induced, the levels of lactate excretion were
significantly reduced (Figure 2F). Similarly, individual knockdown
of LDHA or overexpression of LDHB did not affect tumor
formation (Figure 2G). However, the tumor growth potential
was substantially reduced upon simultaneous reversion
of both LDHA and LDHB in mp53/Ras cells (also known as
LDH-reversed cells) (Figure 2G). Notably, tumors that did arise
following xeno-implantation of LDH-reversed mp53/Ras cell
populations exhibited signs of escape; i.e., LDHA expression
increased and LDHB expression decreased in the tumors (Fig-
ures S4A and S4B), further indicating that LDH reversion is
incompatible with tumor growth. Together, these results suggest
that cooperative oncogene-driven expression changes to spe-
cific LDH isoforms are critical for both LDH enzyme activity
(i.e., lactate production) and tumorigenesis.Oncogenically Induced LDH Isoform Switching Is
Critical for Maintaining TCA Anaplerosis during Hypoxia
LDH activity is critical for both tumorigenesis and proliferation
under hypoxia but not in the presence of atmospheric oxygen
(Fantin et al., 2006; Xie et al., 2014), a notion confirmed in
LDH-reversed mp53/Ras cells (Figures 2G and 3A and 3B). Pro-
longed exposure to hypoxia has been reported to reduce both
mitochondrial membrane potential and ATP concentrations
(Fantin et al., 2006; Figure S4C). The LDH-mediated effects
that initiate the collapse of the malignant state, however, remain
unclear. Here we show that the earliest detectable metabolic
changes following oxygen limitation in LDH-reverted cells not
only include substantial changes to glycolysis and glucose-
mediated biosynthesis but also to glutamine-driven TCA anaple-
rosis (detailed below).
LDH reversion substantially reduced lactate secretion under
hypoxia (Figure 3C). In contrast, glucose consumption rates
were not affected (Figure 3D), indicative of glucose-derived car-
bon being shunted away from lactate because of reduced LDHCell Reports 17, 821–836, October 11, 2016 825
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Figure 3. The Effect of LDH Isoform Reversal under Hypoxia
(A and B) Adherent cell proliferation of vector control (vector) and LDH isoform-reversed (LDH-rev) mp53/Ras cells under 21% oxygen (A) or 1% oxygen (B). Data
are means + SD. *p < 0.01 versus vector control by Student’s t test.
(C and D) Extracellular lactate secretion (C) and glucose consumption (D) at 1% oxygen.
(E) Total intracellular NAD:NADH ratio at 1% oxygen determined by LC-MS/MS.
(F) Schematic of the glycolytic pathway.
(legend continued on next page)
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activity. Notably, under limiting oxygen, LDH serves to regen-
erate nicotinamide adenine dinucleotide (NAD+), which is typi-
cally supplied by respiration, thus providing a rationale for
the hypoxia-specific proliferative dependency of cancer cells
on high LDH activity. Consistent with this scenario, the LDH-re-
verted cells exhibited a lower NAD:NADH ratio under hypoxia
(Figure 3E) but not under non-limiting oxygen (data not shown).
ReducedNAD+ pools can create a glycolytic bottleneck because
NAD+ is required for the reaction catalyzed by GAPDH (Fig-
ure 3F). This bottleneck at GAPDH was observed, with LDH
reversion inducing substantial increases in the glycolytic metab-
olites upstream of GAPDH, including Hexose-P, FBP, and
dihydroxyacetone phosphate (DHAP)/glyceraldehyde 3-phos-
phate (G3P), while reducing the glycolytic metabolites
downstream of GAPDH, such as PEP, pyruvate, and lactate (Fig-
ure 3G). Pentose phosphate pathway (PPP) intermediates were
also affected, with an induction of sedoheptulose-7P and
PRPP (Figure 3G), possibly reflecting increased mass action
flow through PPP resulting from aGAPDH bottleneck. Moreover,
at early time points after oxygen limitation, the levels of several
nucleotides, including ATP, as well as the ATP:ADP ratio, were
similar between control and LDH-reversed cells (Figure 3G),
whereas the levels of alanine, serine, and the TCA cycle metab-
olites malate and a-ketoglutarate (aKG) were substantially
reduced (Figure 3G). The levels of 2-hydroxyglurate (2-HG)
were also reduced in LDH-reversed cells (Figure 3G), consistent
with recent results indicating that LDHA is important for the in-
duction of 2-HG under hypoxic conditions (Intlekofer et al.,
2015), although changes to specific 2-HG enantiomers could
not be resolved from our analysis.
Glucose is a major carbon source for alanine, serine, and
glycine, and the decreased levels of these metabolites could
reflect a decrease in their glucose-derived biosynthesis upon ox-
ygen limitation. Glucose labeling patterns supported this idea,
with LDH reversion decreasing the amount of glucose-derived
alanine, serine, and glycine (Figure 3H; Figure S4D; see Figure S6
for labeling kinetics). Consistent with a compensatory response
to a blockage in serine biosynthesis, the LDH-reverted cells
increased their medium consumption of serine (Figure S4E).
Glucose, via citrate, is also a major source of acetyl-CoA for fatty
acid biosynthesis, which could depend on LDH activity upon
oxygen limitation. Compatible with this hypothesis, LDH-re-
verted cells exhibited decreased fatty acid biosynthesis relative
to vector controls (Figure 3I). Combined, our data indicate that, in
LDH-reversed cancer cells, oxygen limitation produces multiple
defects in glucose-fueled biosynthesis.
Glutamine is a major TCA cycle carbon source in cancerous
cells, a process known as glutamine-driven TCAanaplerosis (De-
Berardinis et al., 2007; Wise et al., 2008; Figure 4A). In addition to(G) Relative intracellular metabolite levels at 1% oxygen determined by LC-MS/M
(B–E) Data are means + SE. *p < 0.01 versus vector control by Student’s t test.
(H) Cells were labeled with 13C-glucose for 90 min at 1% oxygen, and the relative
represent total relative abundance, and the 13C portion represents the sum of
abundance of the indicated metabolite versus that metabolite’s 13C isoform abu
(I) Measurement of fatty acid biosynthesis at 1% oxygen. Data are means + SE.
(C–I) All measurements were made following 8- to 10-hr cell culture in 1% oxyge
See also Figures S4 and S5 and Table S5.glutaminolysis, pyruvate carboxylation can also anaplerotically
replenish TCA cycle pools, an activity that has been found to
be increased in certain tumors (Fan et al., 2009). However, in
contrast to glutamine consumption, expression of oncogenic
Ras and/or mp53 had little effect on the levels of pyruvate
carboxylation (Figures S2C and S2D) suggesting that, in this
context, oncogene expression preferentially drives glutamino-
lytic over pyruvate carboxylation-based TCA anaplerosis. Given
that LDH-reversed cells had reduced malate and aKG levels un-
der hypoxic conditions (Figure 3G), we analyzed how LDH rever-
sion affected glutamine-derived TCA cycle anaplerosis. Oxygen
limitation reduced levels of glutamine-derived aKG, citrate, and
malate in LDH-reversed cells (Figure 4B; Figure S4F), consistent
with the observed decreases in the concentrations of these me-
tabolites (Figure 3G). LDH reversion thus negatively affects the
ability of glutamine to supply TCA cycle pools, suggesting that
glutamine flux into the TCA cycle is partially dependent on LDH
activity under hypoxic conditions.
To explore which metabolic pathways are relevant for cell
proliferation under hypoxia, we assessed whether medium
supplementation with specific metabolites whose levels were
significantly down in LDH-reversed cells could rescue cell prolif-
eration under limiting oxygen. As shown in Figure 4C, medium
supplementation with aKG significantly increased the ability of
LDH-reversed cells to proliferate under hypoxic conditions,
thus indicating its functional relevance to the hypoxic prolifera-
tion defect exhibited by the LDH-reversed cells. Notably, supple-
mentation with aKG did not affect glucose consumption, lactate
secretion, or the NAD:NADH ratio of LDH-reversed cells (Figures
4D–4F), suggesting that the functional effect of aKG supplemen-
tation was independent of LDH’s glycolytic role. Further support-
ing this view, medium supplementation with aKG did not affect
the impact of low oxygen on glycolytic metabolites; i.e., those
pools upstream of GAPDH were still increased and those
downstream of GAPDH were still decreased (Figure 4G). Alanine
pools were also not affected by aKG supplementation, whereas
the decrease in cellular aKGwas rescued (Figure 4G). Similarly to
aKG, medium supplementation with malate also substantially
rescued the proliferation of LDH-reversed cells at low oxygen
concentrations (Figure 4H), further highlighting the importance
of TCA anaplerosis for this phenotype. In contrast, medium sup-
plementation with alanine had no effect on cellular proliferation
(Figure S4G), indicating that decreases in alanine do not play a
critical role in the proliferation defect displayed by the LDH-
reversed cells at low oxygen concentrations. Our data thus point
toward a critical role for LDH in glutamine-driven TCA cycle
anaplerosis under hypoxic conditions, suggesting this is an
essential function of activated glycolysis in facilitating cancer
cell proliferation.S.
abundance of 13C and 12C isoforms was determined by LC-MS/MS. Columns
all detectable isotopologues of a given metabolite. *p < 0.01 for 13C isoform
ndance in vector control cells by Student’s t test. Data are means + SE.
*p < 0.01 versus vector control by Student’s t test.
n.
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GPT2 Is Critical for TCA Anaplerosis and Tumorigenesis
Glutamine-driven TCA anaplerosis requires the transfer of nitro-
gen from glutamate to an acceptor molecule to form aKG. GPT2
transfers glutamate nitrogen to pyruvate, thus forming alanine
and aKG (Figure 5A), making GPT2 a strong candidate for
coupling glycolytic flux to TCA anaplerosis. This reaction readily
occurs in mp53/Ras cells because we observed substantial ni-
trogen transfer from glutamine to alanine after labeling with
a-15N-glutamine (Figure S6C). Moreover, in contrast with LDH
isoform switching, whose TCA contributions only emerge under
limiting oxygen concentrations (see above), the GPT2-catalyzed
transamination would be predicted to contribute to TCA anaple-
rosis irrespective of oxygen availability. Consistent with this pre-
diction, GPT2 expression was not only cooperatively induced in
mp53/Ras cells (Figure 5B), but reversal of this induction via
shRNA-mediated knockdown (Figure 5C) substantially attenu-
ated both glucose-derived alanine labeling (Figure 5D; Fig-
ure S6A) and 13C-glutamine labeling of aKG and citrate under
atmospheric oxygen (Figure 5E; Figure S6B). We thus conclude
that GPT2 plays an essential role in both glutamine-mediated
TCA anaplerosis and the utilization of glucose/glycolysis-derived
pyruvate to drive this activity. GPT2 knockdown also inhibited
cell proliferation at atmospheric oxygen in vitro, an effect that
was restored by medium supplementation either with aKG or
malate (Figure 5F) but not by alanine (Figure S6D), thus linking
the requirement of GPT2 for maximal cell proliferation to its
role in TCA anaplerosis. Pyruvate supplementation did not
rescue proliferation (Figure S6E), consistent with GPT2 knock-
down (kd) blocking the means for pyruvate to drive TCA anaple-
rosis. Pyruvate, on the other hand, does rescue proliferation of
LDH-reversed cells in hypoxia, where pyruvate supply becomes
limiting (Figure S6F). Reduction of GPT2 expression in mp53/
Ras cells also significantly inhibited tumor formation in xenograft
assays (Figure 5G). Moreover, tumors that did arise following
xeno-implantation of GPT2-kd cells were comprised of cells
that had lost knockdown (Figure S6G), further supporting the
idea that low GPT2 expression is incompatible with tumor
growth. In addition, the effect of GPT2 knockdown on tumor
formation and cell proliferation as well as 13C-glucose and
13C-glutmaine labeling could be rescued by expression of an
shRNA-resistant GPT2 allele (Figures 5D–5F), ruling out shRNA
off-target effects as an underlying cause of these phenotypes.
Notably, the GPT2 proliferative requirement emerged only inFigure 4. LDH Supports Glutamine-Driven TCA Anaplerosis under Hyp
(A) Schematic of the tricarboxylic acid (TCA) cycle
(B) Vector control (vector) or LDH-rev mp53/Ras cells were labeled with 13C-glu
determined by LC-MS/MS. Columns represent total relative abundance, and th
metabolite. Measurements were made following 8- to 10-hr cell culture in 1% oxyg
metabolite versus that metabolite’s 13C isoform abundance in vector control cel
(C) Adherent cell proliferation in 1% oxygen and in the presence of 4 mM aKG. D
(D and E) Extracellular lactate secretion (D) and glucose consumption (E) at 1%
(F) Total intracellular NAD:NADH ratio at 1% oxygen determined by LC-MS/MS.
(G) Relative intracellular metabolite levels at 1% oxygen determined by LC-MS/M
(D–G)Measurements weremade following 8- to 10-hr cell culture in 1%oxygen an
versus vector control by Student’s t test.
(H) Adherent cell proliferation in 1% oxygen and in the presence of 4 mM dimethy
cell lines by Student’s t test.
See also Figures S4–S6 and Table S5.the context of malignant cell transformation because GPT2
knockdown did not affect the proliferation of the parental,
immortalized parental, or single oncogene transduced cells
(Figures 5H and 5I). Taken together, our data suggest that
GPT2-mediated TCA cycle anaplerosis is critical and specific
to the cancer phenotype.
GPT2 expression is elevated in human colon cancer tissue
compared with non-tumor control tissue (Figure 6A; Figure S7A).
This increaseappears tobe independent of thep53 andRasmuta-
tional status of these human tumors (Figure S7B), suggesting that
GPT2 induction is a general feature of colon cancers that emerges
as a consequence of malignant transformation rather than being
driven specifically by oncogenic p53 and/or Ras mutations. To
test the importance of GPT2 in a human colon cancer context,
we targeted GPT2 expression with shRNA in two separate human
colon cancer cell lines. GPT2 knockdown substantially reduced
GPT2 expression in both HCT116 and SW480 cells and induced
strong reductions in 13C-glucose-derived alanine labeling (Figures
6B–6E; Figure S7C). Similar to our observations in the murine
system, knockdown of GPT2 in both human cancer lines reduced
13C-glutamine-derived labeling of TCA constituents, including
reduced labeling of aKG, malate, and citrate (Figures 6F and 6G;
Figures S7D and S7E). GPT2 knockdown also substantially in-
hibited the ability of either cell line to form tumors in mice (Fig-
ure 6H&I), as well as induced an in vitro proliferation defect. The
proliferation defect of GPT2-kd cells could be rescued through
malate or aKG medium supplementation (Figures 6J and 6K) but
not alanine or pyruvate supplementation (Figures S7F–S7I).
Notably, the in vivo tumor inhibitory effect of GPT2 knockdown
was phenocopied by knocking down expression of glutaminase
(Figures S7J–S7L), an enzyme that converts glutamine to gluta-
mate. This further supports the functional importance of glutamine
catabolism in GPT2-dependent tumorigenesis. Together, our re-
sults indicate that GPT2 is a critical link between glycolysis and
the TCA cycle that harnesses glycolytically produced pyruvate to
accept glutamine-derived nitrogen, thereby exploiting glycolytic
activation to enable both TCA cycle anaplerosis and themalignant
state of colon cancer cells.
DISCUSSION
Oncogenic transformation of diverse tissue types frequently re-
sults in a global metabolic shift, with activation of both glycolysisoxia
tamine for 90 min, and the relative abundance of 13C and 12C isoforms was
e 13C portion represents the sum of all detectable isotopologues of a given
en. Data are means + SE. *p < 0.01 for 13C isoform abundance of the indicated
ls by Student’s t test.
ata are means + SD. *p < 0.01 versus all other cell lines by Student’s t test.
oxygen.
S.
d in the presence of 4mM aKGwhere indicated. Data aremeans + SE. *p < 0.01
l malate (mal) where indicated. Data are means + SD. *p < 0.01 versus all other
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and glutamine-driven TCA cycle anaplerosis as hallmarks critical
to many cancers. Here we show that these two key features of
cancer cell metabolic reprogramming are causally linked via
coupling of pyruvate production to glutamine catabolism, thus
revealing a critical contribution theWarburg effect makes toward
oncogenesis (Figure 7). Coupling of glycolysis and TCA cycle
anaplerosis occurs at the level of the mitochondrial enzyme
GPT2, which plays an essential role in cancer cell proliferation.
We also show that large-scale metabolic reprogramming by
oncogenic p53 and Ras apparently is not dependent on environ-
mental selective pressures such as oxygen limitation and
acidosis, as suggested previously (Gatenby and Gillies, 2008).
Oncogene-mediated metabolic reprogramming thus not only
preconditions cancer cells to proliferate under adverse condi-
tions but also creates vulnerabilities that may be exploited by
intervention strategies targeting nodes in the metabolic network
critical and specific to cancer cells.
In general, oncogenic p53 and Ras are both required for
driving full cancer cell metabolic reprogramming. In part, the in-
dividual mutations affect metabolic function in distinct ways. For
example, expression of p53175H alone partially induces the levels
of most glycolytic metabolites (Figure 1). These results are
consistent with many reports that p53 inhibits the expression
of glucose transporters while activating expression of negative
regulators of glycolysis (Bensaad et al., 2006; Kawauchi et al.,
2008; Schwartzenberg-Bar-Yoseph et al., 2004; Zhang et al.,
2011). In contrast, although oncogenic Ras12V expression alone
increases glucose consumption slightly, it had little effect on
glycolytic pools, and it actually reduces lactate secretion (Fig-
ure 1). Activated Ras signaling is well known to stimulate glycol-
ysis (reviewed in Bryant et al., 2014); however, its effects are
strongly context-dependent (Baer et al., 2014; Ridley et al.,
1988; To et al., 2013; Vartanian et al., 2013), and the observed
muted effect of oncogenic Ras on glycolysis likely reflects a
requirement for cooperative oncogenic signaling to induce
lactate secretion. In contrast to glycolysis, oncogenic Ras
expression is capable of inducing glutamine consumption (Fig-
ure 1), consistent with the notion that activated Ras is required
for enhanced glutamine metabolism (Gaglio et al., 2011; Son
et al., 2013; Telang et al., 2007). Nevertheless, the full extent ofFigure 5. Cooperative Induction of GPT2 Expression Is Important for G
(A) Schematic of GPT2-mediated coupling of glutamine-driven TCA anaplerosis
(B) GPT2 RNA expression in parental (YAMC) cells or the indicated derivatives of
vector (BN) cells.
(C) GPT2 RNA expression in the indicated derivatives of mp53/Ras cells: v
shRNA-resistant GPT2 cDNA expression (shGPT2/GPT2), or GPT2 overexpressi
(B and C) Expression of GPT2 was measured via real-time PCR using gene-spec
(D and E) Cells were labeled with 13C-glucose (D) or 13C-glutamine (E) for 90 min, a
MS. Columns represent total relative abundance, and the 13C portion represent
13C isoform abundance of the indicated metabolite versus that metabolite’s 13C is
(F) Adherent cell proliferation in the presence of 4 mM aKG or 4 mM dimethyl mala
Student’s t test.
(G) Tumor volumes 4 weeks after 12–18 subcutaneous implantations of the indic
volume is indicated by the horizontal line. *p < 0.01 versus all other cell lines by Stu
by the indicated marker.
(H) GPT2 RNA expression in the indicated derivatives of YAMC, immortalized YAM
(shGPT2). Expression of GPT2 was measured via real-time PCR using gene-spe
(I) Adherent cell proliferation of the indicated YAMC derivatives.
Data are means + SD. See also Figures S5 and S6 and Table S5.these changes only emerged with combined mp53 and onco-
genic Ras expression, with synergistic induction of pathways
such as glycolysis, lactate secretion, glutamine consumption,
and fatty acid biosynthesis (Figure 1). Collectively, our data indi-
cate that cancer cell metabolic reprogramming is a complex pro-
cess and emerges in response to multiple oncogenic mutations.
Tumor-derived tissues exhibit pronounced genetic diversity
and instability, thus complicating the detection of causal rela-
tionships relevant to the process of malignant transformation.
In contrast, our work indicates that cooperating oncogenic mu-
tations can induce a coordinated cancer cell metabolic program
with intrinsic and thus cancer cell-specific metabolic vulnerabil-
ities. In this context, synergistic regulation of LDH isoforms and
GPT2 in response to cooperating oncogenic mutations served
as a powerful identifier of downstream effectors critical to both
carcinogenesis and metabolic reprogramming, although their
regulation, at least in part, may reflect the nature of themalignant
state rather than the identity of oncogenic driver mutations
(Figure S3).
The two LDH isoforms LDHA and LDHB are regulated in oppo-
site directions. Both induction of LDHA and a decrease in LDHB
levels are required for full glycolytic activation and lactate secre-
tion (Figure 2). Conversely, an inhibition of tumorigenesis only
occurredwhen both oncogene-induced changes to LDHmRNAs
were reversed (Figure 2), consistent with the notions that LDHA
exhibits increased activity over LDHB (Read et al., 2001) and
that LDHA expression is critical to tumorigenesis (Fantin et al.,
2006). LDH activity canmaintain glycolysis under limiting oxygen
concentrations by providing NAD+ to the reaction catalyzed by
GAPDH, which is thought to be the enzyme’s major contribution
to tumorigenesis (reviewed in Augoff et al., 2015). Notably, here
we report that LDH dependent glycolytic activity is critical for
generating pyruvate to serve as a nitrogen acceptor for gluta-
mine-driven TCA cycle anaplerosis under hypoxia (Figure 4).
This highlights a link between glycolytically derived pyruvate
and glutamine metabolism that is critical to cancer cell
proliferation.
The coupling between glycolysis and TCA anaplerosis
described here may shed further light on the unexpected finding
that 2HG pools in cancer cells are increased during hypoxia andlutamine-Driven TCA Anaplerosis and Tumorigenesis
to glycolytic production of pyruvate.
YAMC cells: combined mutant (mp53/Ras), mp53 alone, Ras alone, or empty
ector control (vector), GPT2 knockdown (shGPT2), GPT2 knockdown plus
on (GPT2).
ific primers.
nd the relative abundance of 13C and 12C isoforms was determined by LC-MS/
s the sum of all detectable isotopologues of a given metabolite. *p < 0.01 for
oform abundance in all other cell lines by Student’s t test. Data are means + SE.
te where indicated. Data are means + SD. *p < 0.01 versus all other cell lines by
ated derivatives of mp53/Ras cells in the flanks of nude mice. Median tumor
dent’s t test. ‘‘8’’ on the graph indicates the number of data points represented
C (YAMC-im), mp53, or Ras cells: vector control (vector) or GPT2 knockdown
cific primers.
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Figure 6. GPT2 Is Critical for Human Colon Cancer Cell Proliferation
(A) GPT2 RNA expression in human colon tumor versus non-tumor samples. *p < 0.01 versus non-tumor by Student’s t test. The y axis values represent
linear scale.
(legend continued on next page)
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Figure 7. Oncogene-Induced Coupling of
Aerobic Glycolysis and Glutamine-Driven
TCA Cycle Anaplerosis Is Mediated by
GPT2 and Critical to the Cancer Phenotype
Oncogenic mutations induce metabolic repro-
gramming in part through switching expression of
LDHB to LDHA and inducing GPT2 expression,
resulting in both activation and coupling of aerobic
glycolysis and TCA cycle anaplerosis to support
cancer cell proliferation. We suggest that this link
between glycolytically derived pyruvate and gluta-
mine metabolism reflects a critical feature of the
Warburg effect.correlate with LDH activity (Intlekofer et al., 2015; Oldham et al.,
2015). Given that 2-HG is produced from aKG, our findings indi-
cating that aKG levels are dependent on LDH activity suggest
that LDH activity could be important to supply aKG for 2-HG
biosynthesis, a possibility that warrants further investigation.
Our results indicate that malignant cell transformation induces
dependence on the aminotransferase GPT2. Aminotransferases
facilitate amino acid-mediated TCA anaplerosis and are
emerging as critical determinants of oncogenesis. Aspartate
amino transaminase (GOT1) (Son et al., 2013), the branched-
chain amino acid transferase (BCAT1) (To¨njes et al., 2013), and
phosphoserine aminotransferase (PSAT1) (Possemato et al.,
2011) have been found to be essential for tumorigenesis of
pancreatic adenocarcinoma, glioblastoma, and breast cancer
cells, respectively. A requirement of aminotransferase activity
for glutamine-driven anaplerosis in colon cancer has been sug-(B and C) GPT2 RNA expression in the indicated derivatives of HCT116 (B) or SW480 (C) cells: shGFP contro
knockdown-2 (shGPT2-2). Expression of GPT2 was measured via real-time PCR using gene-specific prime
(D–G). Cells were labeledwith 13C-glucose (D and E) or 13C-glutamine (F andG) for 90min, and the relative ab
LC-MS/MS. Columns represent total relative abundance, and the 13C portion represents the sum of all detec
for 13C isoform abundance of the indicated metabolite versus that metabolite’s 13C isoform abundance in s
(B–E) Data are means + SE.
(H and I) Tumor volumes 4 weeks after 12 subcutaneous implantations of the indicated cell lines in the flanks
the horizontal line. *p < 0.01 versus shGFP by Student’s t test.
(J and K) Adherent cell proliferation in the presence of 4 mM aKG or 4 mM dimethyl malate where indicated.
lines, except shGPT2-2, by Student’s t test. **p < 0.01 versus shGFP by Student’s t test.
See also Figures S5 and S7 and Tables S6 and S7.
Cell Rgested previously through in vitro work in-
hibiting GPT2 (Weinberg et al., 2010).
However, direct evidence for a critical
role of GPT2 activity in glutamine-driven
TCA anaplerosis and in vivo tumorigenesis
has been lacking. Here we provide genetic
evidence for in vivo cancer cell GPT2 de-
pendency coupled with the non-essential
nature of GPT2 in non-transformed cells.
GPT2 catalyzes the transfer of glutamate
nitrogen to pyruvate, forming alanine and
aKG in the process. Our findings indicate
that GPT2 is critical for glutamine-driven
TCA anaplerosis and couples glycolytic
pyruvate output to driving glutamine
catabolism in murine and human colon
cancer cells. We also show that the criticalrole of GPT2 for cancer cell proliferation is specific to tumori-
genic cells expressing multiple oncogenic mutations, whereas
proliferation rates of non-tumorigenic cells expressing single
oncogenic mutations or normal parental cells remain unaltered
in response to GPT2 knockdown.
Our work demonstrates in vivo growth dependency of colon
cancer cells on glutamine catabolism. Recent studies on lung
cancer cells have questioned whether the phenomenon of
glutamine addiction observed in vitro is relevant in vivo (David-
son et al., 2016; Hensley et al., 2016). Here we show that
knockdown of both GPT2 and glutaminase (GLS), which
converts glutamine to glutamate, inhibits tumor formation by
human colon cancer cells in xenograft assays. Our results,
along with recent work targeting in vivo glutamine metabolism
in breast cancer cells (Gross et al., 2014; van Geldermalsen
et al., 2016), suggest that the in vivo role of glutaminel (shGFP), GPT2 knockdown-1 (shGPT2-1), or GPT2
rs.
undance of 13C and 12C isoformswas determined by
table isotopologues of a given metabolite. *p < 0.01
hGFP control by Student’s t test.
of nude mice. Median tumor volume is indicated by
Data are means + SD. *p < 0.01 versus all other cell
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metabolism in tumors may be context-dependent. Further
studies are thus needed to elucidate whether certain contexts,
such as tissue of origin, might determine the relevance of can-
cer cell glutamine dependency in vivo.
In summary, our results identify a mechanism through which
the Warburg effect (i.e., cancer-associated glycolytic activation)
contributes to oncogenesis. Although the observation that
cancerous cells frequently activate glycolysis is decades old,
the mechanisms through which it contributes to oncogenesis
have been unclear. Some have postulated that the Warburg
effect contributes through the increased speed of energy gen-
eration associated with glycolysis, although direct evidence
for this hypothesis is limited (reviewed in Liberti and Locasale,
2016). Others have suggested that activated glycolysis contrib-
utes through the production of biosynthetic intermediates (re-
viewed in DeBerardinis et al., 2008). On the other hand, the
bulk of glycolytic carbon is excreted as lactate and alanine
rather than funneled into biosynthesis (Liberti and Locasale,
2016). Although contributions of the above-mentioned path-
ways are possible, our results indicate that the Warburg effect
critically supports oncogenesis through the production of pyru-
vate to accept nitrogen from glutamine catabolism. Notably,
this oncogenic coupling of glucose and glutamine metabolism
is induced by common oncogenic mutations that drive LDH
switching, the induction of GPT2, and the emergence of
specific metabolic vulnerabilities. Many of these metabolic
phenotypes are shared by diverse types of cancer, which sug-
gests the exciting possibility that these metabolic drivers and
vulnerabilities may provide attractive molecular targets for
novel broad-spectrum cancer interventions.
EXPERIMENTAL PROCEDURES
Cells
YAMC cells (Whitehead et al., 1993), YAMC cells with empty vectors (BN), and
YAMC cells expressing p53175H (mp53), HRas12V (Ras), and both p53175H and
HRas12V (mp53/Ras) were derived and maintained as described previously
(McMurray et al., 2008; Xia and Land, 2007). HCT-116 and SW-480 human co-
lon cancer cells were purchased from the ATCC. Both human cell lines were
cultured at 37C in DMEM (Invitrogen) supplemented with 10% fetal bovine
serum (FBS) (Hyclone) and 2.5 mg/mL gentamycin (Invitrogen). Genetically per-
turbed cells were generated by retroviral infection with a virus containing
appropriate shRNA or cDNA expression constructs. The retrovirus used to
infect murine cells and human colon cancer cells was produced by transient
transfection of FNX-eco cells or 293TN cells (ATCC). Infections were carried
out in media supplemented with 8 mg/mL Polybrene to increase infection effi-
ciency. After infection, polyclonal cell populations with stable expression of the
indicated shRNAs and/or cDNAs were generated by selection with 5 mg/mL
puromycin, 5 mg/mL blasticidin, and/or 75 mg/mL hygromycin B.
Adherent Cell Proliferation Assays
Prior to the assay, cells were grown without selective drugs for 48 hr under stan-
dardculture conditions. Cellswere thenplatedunder standard culture conditions
and at the indicated densities. Twenty-four hours after plating, cells were treated
with the indicated concentrations of dimethyl alpha-ketoglutarate (Sigma),
dimethyl malate (Sigma), or L-alanine (Sigma) and cultured under the indicated
oxygen conditions. Cells were counted every 24 hr, and counts were normalized
to cell number at initial time of treatment; i.e., 24 hr after plating the cells.
LC-MS/MS Methodology
Metabolites were extracted with78Cmethanol:water (80:20) prior to analysis
using reverse-phase chromatography with an ion-paring reagent in a Shimadzu834 Cell Reports 17, 821–836, October 11, 2016high-performance liquid chromatography (HPLC) coupled to a ThermoQuantum
triple quadrupole mass spectrometer. Mass spectrometry was performed in
negative mode with selected reaction monitoring (SRM)-specific scans as
described in DeVito et al. (2014) and Munger et al. (2008). Further specifics
regarding labeling, extraction, chromatography, and mass spectrometry data
analysis can be found in the Supplemental Experimental Procedures.
Extracellular Lactate, Glucose, and Glutamine Measurements
Prior to measurement, cells were grown without selective drugs for 48 hr at
39C under standard medium conditions and then cultured for an additional
20 hr without serum. After 20 hr of serum starvation, cells were given fresh
serum free media, and measurements were made 6 hr later using a NOVA bio-
profile basic 4 according to the manufacturer’s instructions (http://www.
novabiomedical.com). For measurements under hypoxia, cells were moved
to 1% oxygen for the indicated time prior to sample collection and analysis.
Results were normalized for protein content measurement by Bradford assay.
Xenograft Assay
Tumor formation was assessed as described previously (McMurray et al.,
2008). Briefly, 5 3 105 mp53/Ras cell derivatives or 2.5 3 106 human colon
cancer cell derivatives were implanted subcutaneously into the flanks of
CD-1 nude mice (Crl:CD-1-Foxn1nu, Charles River Laboratories). Prior to in-
jection, all cells were grown without selective drugs for a minimum of 48 hr
in standard culture medium. Tumor diameters along the x, y, and z axes
were measured by caliper at indicated time points, and the averages of these
three measurements were used to calculate volume, utilizing the formula
volume = (4/3)Pr3. The statistical significance of tumor volume differences
was determined by Student’s t test. All animal procedures conform to the
Association for Assessment and Accreditation of Laboratory Animal Care
International (AAALAC) regulations and were approved by the local University
Committee on Animal Resources.
Statistics
PLS-DA and ANOVA of the metabolite pool size data were performed using the
publicly available software MetaboAnalyst 3.0 (http://www.metaboanalyst.ca)
(Xia et al., 2015). Prior to analysis, protein-normalized concentration data were
corrected for batch effects using the Combat method (Johnson et al., 2007).
Batch-corrected data were subsequently auto-scaled. For PLS-DA, PLS regres-
sionwas performed using the plsr function provided by the R pls package (Mevik
and Wehrens, 2007). Classification and cross-validation were performed using
the corresponding wrapper function offered in the R caret package (Kuhn,
2008). Permutation testing was performed to assess the significance of class
discrimination using the optimal number of components as determined by
leave-one-out cross-validation (LOOCV), which was four components
(FiguresS1CandS1D).Permutation testingof thePLS-DAmodel,with2,000per-
mutations, yielded a p value that was less than 5e4 (Figure S1).
For all experiments in which more than two samples types were compared
(i.e., more than two cell lines), significant features were identified through a
one-way ANOVA of the batch-corrected data, followed by Fisher’s least signif-
icant difference (LSD) post hoc testing. For comparisons between two cell
types, a Student’s t test was employed. In either case, where multiple tests
were performed, p values were corrected using the Benjamini-Hochberg false
discovery rate (FDR) correction.
Metabolic activities were deemed to be cooperative when the activities/pool
size increases for the murine colon cells satisfied the following criteria:
ð½Ras=½YAMC­1+ ½mp53=½YAMC­1Þ=ð½mp53=Ras=½YAMC­1Þ< 0:6:
Metabolic activities or pool size increases were deemed mp53- or Ras
allele-dominant when their fold changes relative to the YAMC cells and the
opposite single mutation were both >2-fold.
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